1 The hypomethylating agents (HMA), azacitidine, and decitabine represent treatment options for elderly AML patients including sAML patients unfit for intensive chemotherapy.
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria.
Between April 2017 and September 2018, seven patients with sAML received venetoclax therapy. Two out of seven patients achieved a complete remission upon venetoclax initiation with a PFS of 505 days and 352 days and another patient achieved complete peripheral blood blast clearing within nine days after start of venetoclax.
Among the venetoclax responders, primary refractory disease to prior HMA therapy was documented, 2 patients harbored IDH1/IDH2 mutations and one patient had an antecedent myeloproliferative neoplasm. High BCL-2 and/or BIM expression in myeloblasts was found in venetoclax responders and response was significantly associated with overall survival (responders: 364 days versus non-responders: 24 days, P = 0.018). Venetoclax monotherapy is safe and is able to induce durable responses in elderly patients with secondary AML after treatment failure with HMA.
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| INTRODUC TI ON
Secondary acute myeloid leukemia (sAML) evolving from an antecedent hematological disorder and therapy-related sAML represent high-risk subsets of AML and are associated with poor clinical outcome.
1 The hypomethylating agents (HMA), azacitidine, and decitabine represent treatment options for elderly AML patients including sAML patients unfit for intensive chemotherapy. 
| PATIENTS AND ME THODS
Included patients were diagnosed with relapsed/refractory AML defined by the World Health Organization classification 15 and con- These findings should be validated in future clinical trials. 
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